Investors looking for opportunities on the Australian Securities Exchange (ASX) should consider seven promising stocks currently making waves in the market. Recent comments from Michele Bullock, the Governor of the Reserve Bank of Australia (RBA), indicate a shift in monetary policy that may impact investment strategies. On December 9, 2024, Bullock stated there are no anticipated interest rate cuts on the horizon, suggesting a tightening bias that could influence market conditions.
Bullock emphasized that the RBA board will assess economic trends closely in the coming months. According to Bloomberg’s Swati Pandey, this clear signal from Bullock surprised many analysts who were expecting the bank to maintain its current rates. Pandey noted that with inflation pressures and economic performance in mind, the possibility of rate hikes is more likely than cuts in the near future.
Key ASX Stocks to Watch
To compile a list of the best ASX stocks to buy, analysis was conducted using data from Finviz and Yahoo stock screeners to identify companies that are dual-listed in the United States and Australia. Stocks were then ranked based on the number of hedge fund holders, utilizing Insider Monkey’s Hedge Fund database for Q3 2024. The following seven stocks stand out for their potential:
1. Immuron Limited (NASDAQ:IMRN)
Number of Hedge Fund Holdings: 1
Immuron Limited, a biotechnology firm, recently faced a setback when its clinical trial for an ETEC hyperimmune bovine colostrum product failed to meet its primary endpoint, causing a 25.8% decline in share price. Despite this, the company received clearance from the FDA for its IMM-529 drug, aimed at treating Clostridioides difficile infection, with a phase 2 trial expected to begin in the first half of 2026.
2. Radiopharm Theranostics Limited (NASDAQ:RADX)
Number of Hedge Fund Holdings: 2
This biotechnology company focuses on treatments for brain metastasis and prostate cancer. On November 26, B. Riley adjusted its share price target for Radiopharm to $13, while maintaining a Buy rating. The firm is making significant progress with its RAD 101 and RAD 204 compounds, which have shown promising clinical results.
3. Immutep Limited (NASDAQ:IMMP)
Number of Hedge Fund Holdings: 2
Immutep Limited has gained attention following an agreement with Dr. Reddy’s Laboratories Ltd. for the development of its Eftilagimod Alfa medicine, receiving a $20 million upfront payment. Positive results from phase one and phase two studies indicate strong potential efficacy in cancer treatment, particularly when combined with existing therapies.
4. Mesoblast Limited (NASDAQ:MESO)
Number of Hedge Fund Holdings: 2
Mesoblast Limited’s Ryoncil drug has been upgraded by Jefferies to a Buy rating, with a price target increase to AUD3.30. The drug generated $30 million in gross revenue in its fiscal second quarter. Its recent J-Code designation by Medicare and Medicaid enhances its market accessibility, marking a significant milestone for the company.
5. Telix Pharmaceuticals Limited (NASDAQ:TLX)
Number of Hedge Fund Holdings: 2
Telix Pharmaceuticals is advancing its prostate cancer therapy candidate, TLX591, and commenced dosing in part two of its phase three study on December 8. The company reported substantial revenue growth of 53% year-on-year, aided by its imaging products.
6. Woodside Energy Group Ltd (NYSE:WDS)
Number of Hedge Fund Holdings: 10
On December 10, Woodside was awarded significant drilling rights in the Gulf of Mexico, with high bids totaling $279 million. The company also reported extracting over 50 million barrels of oil from its Sangomar oilfield in Senegal, despite ongoing arbitration concerning tax disputes with the Senegalese government.
7. BHP Group (NYSE:BHP)
Number of Hedge Fund Holdings: 24
As one of the largest mining companies globally, BHP announced a $2 billion investment from BlackRock’s Global Infrastructure Partners for its Western Australia Iron Ore operations. Analysts have shown confidence in BHP’s growth, with increasing share price targets from major financial institutions.
Understanding the movements of hedge funds can provide valuable insights for investors. Research indicates that mimicking top hedge fund picks can lead to superior market performance. As investors consider their next steps in the ASX, these seven stocks present compelling opportunities based on recent developments and market trends.
